Validation of the falling stick test as screening test device for prodromal neurodegenerative diseases - FALL-DEG

Hans Berger Klinik für Neurologie, Universitätsklinikum Jena0 个研究点目标入组 111 人开始时间: 2022年10月12日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Group 1: Patients of any gender with idiopathic REM sleep behavior disorder (prodromal Parkinson's disease) without parkinsonoid movement deficits, Age >= 18 years
•Group 2: Patients of any gender with amnestic Mild Cognitive Impairment (prodromal Alzheimer's disease), Age >= 18 years
•Group 3: Healthy control participants of any gender, adapted for age and gender, Age >= 18 years

•presence of a disease which could potentially impair the motor function or responsiveness, including the following:
•- neurological diseases:
•o history of stroke
•o history of cerebral haemorrhage
•o multiple sclerosis
•o history of meningitis or encephalitis
•o chronic headache or migraine (duration > 3 months, minimum of 15 days per month)
•o brain tumour
•o pronounced polyneuropathy with impairment of the upper extremities
•o neurodegenerative disease
•-->Parkinson's disease
•--> Alzheimer's disease or a different type of dementia
•- presentation of a presently treated, oncological disease
•- severe sight disorder that cannot be adjusted for by use of a visual aid
•- presentation of a cardiological disease with impaired left or right ventricular pump function (NYHA III-IV)
•- presentation of an orthopedic disease/injury/dysfunction that is ongoing or was present in the last 6 months, impairs the grip function and affects one or multiple of the following localisations:
•o upper extremity (hand, finger, wrist, elbow)
•o cervical spine
•o thoracis spine
•- centrally acting medication that possibly impairs the motor function or responsiveness

发起方

Hans Berger Klinik für Neurologie, Universitätsklinikum Jena